Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTABNSJ)

DTT Name Pyruvate kinase (PK)
Gene Name PK
DTT Type
Clinical trial target
 [1]
BioChemical Class
Kinase
UniProt ID
NOUNIPROTAC
TTD ID
T31458

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etavopivat DMXOHYH Sickle-cell disorder 3A51 Phase 2/3 [2]
AGS-348 DMDUIO4 Hereditary angioedema 4A00.14 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Agios Pharmaceuticals.
2 Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219.